Skip to content

close

R&D

homeHOME R&D Major Achievements

Major Achievements

Partners: SpineBiophama, YH14618 - $218,150,000, 2018.7.26 / Partners: Janssen, LECLAZA® (Lazertinib) - $1,255,000,000, 2018.11.5 / Partners: GILEAD, YHC1102, YHC1108 - $785,000,000, 2019.1.17 / Partners: Boehringer Ingelheim, YH25724 - $870,000,000, 2019.7.1 / Partners: Processa Pharmaceuticals, YH12852 - $410,500,000, 2020.8.20

YH14618 LECLAZA®
(Lazertinib)		 YH33619,
YHC1108		 YH25724 YH12852
Licensor Spine Biopharma
(US)		 Janssen Biotech
(US)		 Gilead Sciences
(US)		 Boehringer
Ingelheim
(Germany)		 Processa
Pharmaceuticals
(US)
Indication Degenerative
Disc Disease		 Non small cell lung cancer Nonalcoholic
steatohepatitis		 Nonalcoholic
steatohepatitis		 Functional GI
motility-related
disorders
Development
stage		 Ph 2 clinical study

• Launched in Korea (second-line monotherapy)

• Global Ph 3 study (first-line monotherapy)

• Global Ph 3 study (first-line combination therapy)

• Global Ph 1/1b study (incl. third-line combination therapy for osimertinib-relapsed NSCLC)

 Lead candidate Ph 1 clinical study Ph 2 clinical study
Key
milestone(s)
in 2022		 Entering late-stage
clinical study
in the US

Global clinical studies

 Initiation of
preclinical studies		 Conduct Ph 1 clinical study in EU Conduct Ph 2 clinical study in the US